Exploratory study to examine the effect of Ramelteon on end of life delirium

Exploratory study to examine the effect of Ramelteon on end of life delirium - Exploratory study to examine the effect of Ramelteon on end of life delirium

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000027787

Enrollment

Registered

2017-06-23

Start date

2017-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced cancer

Interventions

Ramelteon 8mg/day

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. In palliative care unit 2. Possible to take medicine orally 3. Cancer associated pain is well controlled 4. Life expectancy is shorter than 1 months 5. Written informed consent

Exclusion criteria

Exclusion criteria: 1. Having regular use of antipsychotics, antidepressants, antimanics and anticonvulsants. 2. Dementia 3. Serious complications such as liver failure, respiratory insufficiency, heart failure, or renal failure 4. Alcoholism or psychiatric patients 5. Already diagnosed delirium 6. Symptomatic intracranial lesions

Design outcomes

Primary

Measure	Time frame
The incidence of delirium in a week	—

Countries

Japan

Contacts

Public ContactYusuke Hiratsuka

Tohoku University School of Medicine Department of Palliative Medicine

yusuke.hiratsuka.e6@tohoku.ac.jp022-717-7366

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026